Poster Presentation at International mRNA Health Conference Showcases Clinical Evidence that PharmaJet® Delivery Systems Enable mRNA Vaccine Delivery
Portfolio Pulse from
PharmaJet's needle-free technology has been shown to enhance the immune response of mRNA vaccines and is being integrated into various vaccine development programs.
November 12, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PharmaJet's needle-free technology, which enhances mRNA vaccine immune response, could benefit companies like Moderna that are involved in mRNA vaccine development.
PharmaJet's technology is relevant to Moderna as it could enhance the effectiveness of their mRNA vaccines, potentially leading to better market performance and adoption.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50